NervGen narrows Q1 loss and achieves FDA alignment for Phase 3 trial
NervGen Pharma (NASDAQ:NGEN) reported its financial results and operational updates for the first quarter ended March 31, 2026, highlighting clinical milestones for its lead compound and its recent successful transition to a major U.S. exchange.










